Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
About Us
HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene editing tools and gene therapies to rewrite the future of genomic medicine. Based in Shanghai and New Jersey, HuidaGene is committed to addressing patients’ needs globally with various therapeutic programs covering neurology, ophthalmology and neuromuscular. HuidaGene is committed to delivering cutting-edge gene editing tools and providing precise, safe, and effective one-and-done treatments for patients living with life-threatening conditions worldwide by repairing the cause of their disease. We are committed to transforming the future of genome-editing medicine.
Our Mission
&
Vision
Growth Footprint
-
2018
Oct. Incorporation of HuidaGene in Shanghai
Nov. Completion of Angel round of funding
-
2019
Feb. Completion of the R&D lab
Nov. Completion of Series A financing
-
2020
Nov. Completion of CMC Lab (Shanghai Waigaoqiao Free Trade Zone）
-
2021
Feb. Discovery of CRISPR-Cas13X/Y tool
May. Completion of Series B financing
Nov. Discovery of CRISPR/Cas12 tool
Dec. Completion of first external licensing partnership with Cas13X/Y RNA editing tool
-
2022
Jan. Cas13X/Y patent granted by USPTO
May. Completion of Series C financing
Sept. RNA Base Editor-Cas13X patent granted by CNIPA
-
2023
Jan. IND clearance for the multinational clinical trial of HG004 (Study HG00402) to treat RPE65 mutation-associated inherited retinal diseases (RPE65-IRDs) by FDA
Jan. First patient dosed in the HG004 IIT (study HG00401)
Mar. HG004 granted Orphan Drug Designation(ODD) by FDA
Apr. IND approval of the multi-national clinical trial of HG004 (Study HG00402) by China NMPA
May. Cas12i patent granted by USPTO
May. Discovery of glycosylase-based guanine base editor (gGBE)
Aug. HG004 granted Rare Pediatric Disease Designation (RPDD) by FDA
Aug. HuidaGene and Kactus announced licensing partnership on hfCas12Max
Sep. First patient dosed of the world's first novel CRISPR/Cas13 RNA-editing therapy, HG202 for the treatment of nAMD
Oct. FDA granted ODD and RPDD to HG204 for the treatment of MECP2 Duplication Syndrome
Oct. Last Patient Dosed in HG004 IIT (Study HG00401)
Nov. First Patient Dosed in Multnational Phase 1/2 Trial of HG004 (Study HG00402)
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023